Related Experiment Video
Updated: Nov 5, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis
Hans-Peter Hartung1,2,3, Sven G Meuth1, Deborah M Miller4
1Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany.
Purpose Of Review:
To assess the reasons for considering discontinuation of disease-modifying therapies (DMTs)in patients with multiple sclerosis (MS). Relevant aspects of the natural history, pathology, and immunology are analyzed.
Recent Findings:
A number of retrospective observational studies in aggregate indicate that stopping DMTs may be attempted in older individuals with stable disease. Prognostic factors have been identified informing about the risk of recurrence of disease activity after DMT discontinuation.
Summary:
Several clinical scenarios provide a rationale to stop DMTs in people with MS. Cumulative evidence has been gathered recently allowing us to more precisely weigh the risks against the benefits. This information aids in the decision process.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Alzheimer's Disease: Treatment
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Drug Therapy
Antianxiety Medications
Therapeutic Drug Monitoring: Affecting Factors

